HMGA1 and acute myeloid leukemia: Furthermore, HMGA1 deficiency in JAK2V617F AML cell lines enhances responses to the JAK inhibitor, ruxolitinib, disrupting leukemic engraftment and expansion while prolonging survival in recipient immunosuppressed mice [48].